2019
DOI: 10.1159/000497292
|View full text |Cite
|
Sign up to set email alerts
|

Immunotherapy in Esophagogastric Adenocarcinoma

Abstract: Immunotherapy, particular PD-1/L1 inhibition, is a relevant treatment approach in esophagogastric adenocarcinoma. To date, single-agent activity is limited to the chemotherapy refractory setting and molecularly defined subgroups. Currently, ongoing trials, which are likely to relevantly change the landscape of treatment for this disease in the next years, evaluate different combination approaches with chemotherapy and/or molecular targeted agents in different disease settings. The German AIO study group has la… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 24 publications
0
3
0
Order By: Relevance
“…20 It is worth noting that immunotherapy associated with PD-1/L1 inhibition has been proposed as a treatment measure for esophagogastric adenocarcinoma. 41 These findings suggest that knockdown of SPOP may increase PD-L1 expression and provide…”
Section: Discussionmentioning
confidence: 90%
See 1 more Smart Citation
“…20 It is worth noting that immunotherapy associated with PD-1/L1 inhibition has been proposed as a treatment measure for esophagogastric adenocarcinoma. 41 These findings suggest that knockdown of SPOP may increase PD-L1 expression and provide…”
Section: Discussionmentioning
confidence: 90%
“…Additionally, OE of PD‐L1 is considered as a pivotal prognostic factor for poor overall survival of EAC patients undergoing surgical treatment 20 . It is worth noting that immunotherapy associated with PD‐1/L1 inhibition has been proposed as a treatment measure for esophagogastric adenocarcinoma 41 . These findings suggest that knockdown of SPOP may increase PD‐L1 expression and provide support for promotive role of PD‐L1 in immune escape of EAC cells.…”
Section: Discussionmentioning
confidence: 93%
“…Some studies tested single agent regimes, some ongoing trials evaluate combination approaches with chemotherapy and/or molecular targeted agents in different disease settings. Most studies test PD-L1 IHC as predictive biomarker, e.g., [12][13][14]. The most common type of interpretation is the IHC combined positive score (CPS) [15] which evaluates PD-L1 expression on carcinoma cells and tumor-associated immune cells.…”
Section: Introductionmentioning
confidence: 99%